Insmed Incorporated
INSM
Κατάταξη σε μετοχές
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Τιμή μετοχής
$95.88
Κεφαλαιοποίηση
$20.94B
Αλλαγή (1 ημέρα)
0.61%
Αλλαγή (1 έτος)
-42.90%
Χώρα
US
Εμπόριο Insmed Incorporated (INSM)
Κατηγορία
Healthcare
Δείκτης P/B για Insmed Incorporated (INSM)
Δείκτης P/B στις October 2026 TTM: 28.06
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Insmed Incorporated, ο τρέχων δείκτης P/B (TTM) είναι 28.06. Στο τέλος του 2023, η εταιρεία είχε P/B δείκτη -13.11.
Ιστορικό P/B για την Insmed Incorporated από 2000 έως 2026
Δείκτης P/B στο τέλος κάθε έτους
| Έτος | Δείκτης P/B | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 28.06 | -29.30% |
| 2024 | 39.69 | -402.68% |
| 2023 | -13.11 | -146.91% |
| 2022 | 27.95 | 275.67% |
| 2021 | 7.44 | -36.83% |
| 2020 | 11.78 | 52.62% |
| 2019 | 7.72 | 59.41% |
| 2018 | 4.84 | -15.80% |
| 2017 | 5.75 | 8.54% |
| 2016 | 5.30 | 55.48% |
| 2015 | 3.41 | -4.67% |
| 2014 | 3.57 | -13.87% |
| 2013 | 4.15 | 182.67% |
| 2012 | 1.47 | 176.73% |
| 2011 | 0.53 | 22.38% |
| 2010 | 0.43 | -45.13% |
| 2009 | 0.79 | -103.91% |
| 2008 | -20.23 | -345.58% |
| 2007 | 8.24 | 36.28% |
| 2006 | 6.04 | -33.73% |
| 2005 | 9.12 | -23.38% |
| 2004 | 11.90 | 195.16% |
| 2003 | 4.03 | 549.88% |
| 2002 | 0.62 | -70.50% |
| 2001 | 2.10 | 220.36% |
| 2000 | 0.66 | 0.00% |
Δείκτης P/B για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Δείκτης P/B | Διαφορά Δείκτη P/B | Χώρα |
|---|---|---|---|
| 6.251 | -77.72% |
US
|
|
| 13.2547 | -52.76% |
US
|
|
| 4.208 | -85.00% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.97% |
NL
|
